CA2457362C - Anticorps monoclonaux humains neutralisant le virus de la rage et les procedes de fabrication et d'utilisation desdits anticorps - Google Patents

Anticorps monoclonaux humains neutralisant le virus de la rage et les procedes de fabrication et d'utilisation desdits anticorps Download PDF

Info

Publication number
CA2457362C
CA2457362C CA2457362A CA2457362A CA2457362C CA 2457362 C CA2457362 C CA 2457362C CA 2457362 A CA2457362 A CA 2457362A CA 2457362 A CA2457362 A CA 2457362A CA 2457362 C CA2457362 C CA 2457362C
Authority
CA
Canada
Prior art keywords
ser
val
thr
leu
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2457362A
Other languages
English (en)
Other versions
CA2457362A1 (fr
Inventor
Douglas C. Hooper
Bernhard Dietzschold
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of CA2457362A1 publication Critical patent/CA2457362A1/fr
Application granted granted Critical
Publication of CA2457362C publication Critical patent/CA2457362C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des anticorps de recombinaison. Cette invention concerne aussi l'acide nucléique et les séquences d'amino acides codées de la chaîne lourde et légère d'immunoglobulines d'anticorps monoclonaux humains neutralisant le virus de la rage et l'utilisation de ceux-ci.
CA2457362A 2001-08-21 2002-08-21 Anticorps monoclonaux humains neutralisant le virus de la rage et les procedes de fabrication et d'utilisation desdits anticorps Expired - Fee Related CA2457362C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31402301P 2001-08-21 2001-08-21
US60/314,023 2001-08-21
PCT/US2002/026584 WO2003016501A2 (fr) 2001-08-21 2002-08-21 Anticorps de recombinaison, compositions et techniques de fabrication et d'utilisation de ces anticorps

Publications (2)

Publication Number Publication Date
CA2457362A1 CA2457362A1 (fr) 2003-02-27
CA2457362C true CA2457362C (fr) 2012-01-17

Family

ID=23218208

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2457362A Expired - Fee Related CA2457362C (fr) 2001-08-21 2002-08-21 Anticorps monoclonaux humains neutralisant le virus de la rage et les procedes de fabrication et d'utilisation desdits anticorps

Country Status (10)

Country Link
EP (1) EP1530579B1 (fr)
CN (1) CN1636019B (fr)
AT (1) ATE557040T1 (fr)
AU (1) AU2002332600B2 (fr)
CA (1) CA2457362C (fr)
HK (1) HK1071898A1 (fr)
MX (1) MXPA04001609A (fr)
NZ (1) NZ531291A (fr)
RU (1) RU2292353C2 (fr)
WO (1) WO2003016501A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
CN101537180B (zh) 2002-07-18 2016-02-10 莫鲁斯有限公司 抗体混合物的重组生产
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
ES2408582T3 (es) * 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005000225A2 (fr) * 2003-06-02 2005-01-06 University Of Oxford Production d'anticorps contre la rage dans des plantes
DK1737971T3 (da) 2004-01-20 2017-11-13 Merus Nv Blandinger af bindingsproteiner
RS53269B (en) * 2004-05-27 2014-08-29 Crucell Holland B.V. BINDING MOLECULES WHICH MAY NEUTRALIZE FRAGILE VIRUS AND USE
EP1941043B1 (fr) * 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Procede d'expression par recombinaison d'un polypeptide
CN101100663B (zh) * 2006-07-05 2011-08-24 华北制药集团新药研究开发有限责任公司 重组人抗狂犬病毒单克隆抗体的制备方法
KR101522036B1 (ko) 2006-12-05 2015-05-20 크루셀 홀란드 비.브이. 액체 항-광견병 항체 조성물
CN101337990B (zh) * 2008-06-25 2011-04-06 中国人民解放军军事医学科学院微生物流行病研究所 人源抗狂犬病毒中和性抗体及其制备方法与用途
CN101696242B (zh) * 2009-10-26 2011-12-28 中国人民解放军南京军区军事医学研究所 人源抗狂犬病毒中和抗体Fab及其制备方法和应用
PT2838918T (pt) 2012-04-20 2019-08-23 Merus Nv Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig
RU2682677C2 (ru) * 2017-09-07 2019-03-20 Федеральное бюджетное учреждение науки "Екатеринбургский научно-исследовательский институт вирусных инфекций" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ЕНИИВИ" Роспотребнадзора) Способ постэкспозиционной профилактики клещевого энцефалита

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1282703B1 (fr) * 2000-05-16 2008-10-15 Thomas Jefferson University Anticorps monoclonaux humains de neutralisation du virus de la rage, acides nucleiques et procedes associes

Also Published As

Publication number Publication date
EP1530579A2 (fr) 2005-05-18
AU2002332600B2 (en) 2007-03-22
ATE557040T1 (de) 2012-05-15
EP1530579B1 (fr) 2012-05-09
RU2292353C2 (ru) 2007-01-27
CN1636019B (zh) 2010-06-16
EP1530579A4 (fr) 2006-02-08
WO2003016501A3 (fr) 2005-03-24
WO2003016501A2 (fr) 2003-02-27
NZ531291A (en) 2006-02-24
CA2457362A1 (fr) 2003-02-27
RU2004108115A (ru) 2005-09-27
CN1636019A (zh) 2005-07-06
MXPA04001609A (es) 2005-03-07
HK1071898A1 (en) 2005-08-05

Similar Documents

Publication Publication Date Title
CA2457362C (fr) Anticorps monoclonaux humains neutralisant le virus de la rage et les procedes de fabrication et d'utilisation desdits anticorps
CN107406508B (zh) 人源化的抗trop-2单克隆抗体及其应用
KR101413785B1 (ko) Dickkopf-1 및/또는 -4의 항체에 대한 조성물 및 사용 방법
KR101896124B1 (ko) 항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
KR20220167273A (ko) 항-코로나바이러스 항체 및 사용 방법
CA2721713C (fr) Anticorps a reaction croisee anti-il-17a/il-17f et leurs procedes d'utilisation
TW202216757A (zh) 中和性抗sars-cov-2抗體及其使用方法
KR20120088551A (ko) 보체 단백질 c3b를 표적화하는 항체를 위한 조성물 및 방법
CA2419148C (fr) Anticorps monoclonaux humains de neutralisation du virus de la rage, acides nucleiques et procedes associes
CN108135999B (zh) 针对狂犬病的人抗体及其用途
CN111333723B (zh) 针对狂犬病病毒g蛋白的单克隆抗体及其用途
JP6055763B2 (ja) ヒトサイトメガロウイルス(CMV)gBタンパク質に対する高親和性ヒト抗体
US10689434B2 (en) Antibody against hepatitis B surface antigen and use thereof
KR20210041586A (ko) 항-cxcr2 항체 및 이의 용도
AU2002332600A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
KR101729458B1 (ko) 핵산
US20030157112A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
CN113956352B (zh) 新型冠状病毒中和性抗体及其制备方法与用途
US20040013672A1 (en) Recombinant antibodies, and compositions and methods for making and using the same
RU2807067C2 (ru) Антитела против CXCR2 и их применение

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200831